Cholangiopathies Overview

Principles

Definition

Cholangiopathies is a research field dedicated to the study of a spectrum of chronic diseases affecting the biliary tract, investigating their complex pathogenesis involving cholangiocyte dysfunction, inflammation, and progressive liver injury leading to fibrosis and cirrhosis, with the aim of developing effective therapeutic interventions for these conditions which currently have limited treatment options.

Ontological type

Therapeutic Strategies

Molecular Pathogenesis

Disease Classification

Key developments

Key Figures

Autoimmune Diagnostic Paradigm era

Sheila Sherlock [1] was a leading hepatologist at University of California, San Francisco [3] and University of Pittsburgh [4]. Her 1973 paper The Presentation and Diagnosis of 100 Patients with Primary Biliary Cirrhosis [7] clarified clinical presentation and diagnostic criteria, the 1983 paper Association of primary sclerosing cholangitis with HLA-B8 [8] highlighted genetic associations, and the 1986 paper Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis [9] linked serology with disease associations, together underpinning serology-driven taxonomy and prognostication in the era. E. Rolland Dickson [2] was associated with University of Minnesota [5] and University of Toronto [6]. His sole 1978 paper Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) [10] advanced staging concepts and the integration of histopathology with the clinical syndrome, supporting prognostic assessment in autoimmune cholangiopathies.

Immunogenetic and Epithelial Mechanisms era

David A. Brenner [1], affiliated with La Roche College [3] and Johns Hopkins University [4] during this era, contributed to cholangiopathy research. His key contribution is the 2007 paper 'TLR4 enhances TGF-β signaling and hepatic fibrosis' [7], which linked TLR4-driven innate immune signaling to augmented TGF-β activity and hepatic fibrogenesis, illustrating how immunogenetic and epithelial mechanisms drive duct remodeling in cholangiopathies. Ekihiro Seki [2] conducted work across affiliations including University of California, San Diego [5] and Heidelberg University [6] during this era. His key contribution, as reflected in the same 2007 paper 'TLR4 enhances TGF-β signaling and hepatic fibrosis' [7], demonstrated that TLR4 signaling can amplify fibrogenic pathways in hepatic tissue, underscoring the importance of immunogenetic and epithelial interactions for disease susceptibility and translational potential in cholangiopathies.

Bile Acid Immunometabolism era

Robert F. Schwabe[1] is a leading scholar whose work spans Stanford University[3] and the University of Massachusetts Chan Medical School[4] in this era. His fate tracing has revealed hepatic stellate cells[6] as dominant contributors to liver fibrosis independent of its aetiology, and he showed deactivation of hepatic stellate cells during fibrosis resolution in mice[7]. David A. Brenner[2] is a prominent figure affiliated with Stanford University[3] and the University of California, San Diego[5] in this line of work. His notable contributions include myofibroblasts[8] revert to an inactive phenotype during regression of liver fibrosis, and interleukin-17 signaling[9] in inflammatory and hepatic stellate cells exacerbates liver fibrosis in mice, underscoring immunometabolic pathways as therapeutic targets.